Myrbetriq

Chemical Namemirabegron
Dosage FormTablets (oral; 25mg, 50mg)
Drug ClassReceptor agonists
SystemUrinary
CompanyAstellas Pharma US
Approval Year2012

Indication

  • For the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Last updated on 12/15/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Myrbetriq (mirabegron) Prescribing Information2012Astellas Pharma US Inc., Northbrook, IL